{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:43:47Z","timestamp":1791287027039,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Interleukin (IL)-15 is a proinflammatory cytokine, as it induces the production of inflammatory cytokines [IL-6, tumor necrosis factor \u03b1 (TNF\u03b1), IL-17, etc.]. A correlation between high intratumoral IL-15 concentrations and poor clinical outcome in lung and head and neck cancer patients has been recently reported. The purpose of this study was to investigate the role of the soluble \u03b1 chain of IL-15 receptor (sIL-15R\u03b1), a natural regulator of IL-15, in head and neck cancer. Fifty-three newly diagnosed untreated head and neck cancer patients were included in this study. Quantification of sIL-15R\u03b1 was performed with a newly developed RIA. Increased serum sIL-15R\u03b1 concentrations were found in head and neck cancer patients and were closely correlated with poor clinical outcome both in terms of locoregional control and survival even on multivariate analysis. sIL-15R\u03b1 was mainly produced by tumor cells via proteolytic cleavage of IL-15R\u03b1 mediated by ADAM-17. A correlation was observed between ADAM-17 expression in tumor cells and serum sIL-15R\u03b1 concentrations. Surprisingly, sIL-15R\u03b1 did not act in vitro as an IL-15 antagonist but rather as an enhancer of IL-15\u2013induced proinflammatory cytokines (IL-6, TNF\u03b1, and IL-17) that may promote tumor progression. This new tumor evasion mechanism based on amplification of the intratumoral inflammatory reaction is probably not restricted to head and neck cancer, as other tumors have been shown to release sIL-15R\u03b1. Overall, these results support for the first time an original protumor role of sIL-15R\u03b1 in cancer. [Cancer Res 2008;68(10):3907\u201314]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-6842","type":"journal-article","created":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T14:14:48Z","timestamp":1210860888000},"page":"3907-3914","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["The Soluble \u03b1 Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer"],"prefix":"10.1158","volume":"68","author":[{"given":"Ce\u0301cile","family":"Badoual","sequence":"first","affiliation":[{"name":"1EA 4054 Universite\u0301 Paris Descartes, Faculte\u0301 de Medecine; Ecole Nationale Ve\u0301te\u0301rinaire d'Alfort, Maisons-Alfort, France;"},{"name":"2Service d'Anatomie Pathologique, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gre\u0301gory","family":"Bouchaud","sequence":"additional","affiliation":[{"name":"8Institut National de la Sante et de la Recherche Medicale, UMR 892, Groupe de Recherche Cytokines et Re\u0301cepteurs, Institut de Biologie, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour El Houda","family":"Agueznay","sequence":"additional","affiliation":[{"name":"1EA 4054 Universite\u0301 Paris Descartes, Faculte\u0301 de Medecine; Ecole Nationale Ve\u0301te\u0301rinaire d'Alfort, Maisons-Alfort, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Mortier","sequence":"additional","affiliation":[{"name":"8Institut National de la Sante et de la Recherche Medicale, UMR 892, Groupe de Recherche Cytokines et Re\u0301cepteurs, Institut de Biologie, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ste\u0301phane","family":"Hans","sequence":"additional","affiliation":[{"name":"3Department of Otorhinolaryngology-Head and Neck Surgery, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gey","sequence":"additional","affiliation":[{"name":"4Service d'Immunologie Biologique, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahima","family":"Fernani","sequence":"additional","affiliation":[{"name":"1EA 4054 Universite\u0301 Paris Descartes, Faculte\u0301 de Medecine; Ecole Nationale Ve\u0301te\u0301rinaire d'Alfort, Maisons-Alfort, France;"},{"name":"4Service d'Immunologie Biologique, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u0301verine","family":"Peyrard","sequence":"additional","affiliation":[{"name":"5Centre d'Investigations Cliniques, Assistance Publique des Hopitaux de Paris;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Laurent","family":"-Puig","sequence":"additional","affiliation":[{"name":"6Universite\u0301 Paris-Descartes, Institut National de la Sante et de la Recherche Medicale, UMR-S775;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bruneval","sequence":"additional","affiliation":[{"name":"2Service d'Anatomie Pathologique, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Sastre","sequence":"additional","affiliation":[{"name":"7Service d'Anatomie Pathologique, Institut Curie, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Plet","sequence":"additional","affiliation":[{"name":"8Institut National de la Sante et de la Recherche Medicale, UMR 892, Groupe de Recherche Cytokines et Re\u0301cepteurs, Institut de Biologie, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Garrigue-Antar","sequence":"additional","affiliation":[{"name":"8Institut National de la Sante et de la Recherche Medicale, UMR 892, Groupe de Recherche Cytokines et Re\u0301cepteurs, Institut de Biologie, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327oise","family":"Quintin-Colonna","sequence":"additional","affiliation":[{"name":"1EA 4054 Universite\u0301 Paris Descartes, Faculte\u0301 de Medecine; Ecole Nationale Ve\u0301te\u0301rinaire d'Alfort, Maisons-Alfort, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf H.","family":"Fridman","sequence":"additional","affiliation":[{"name":"4Service d'Immunologie Biologique, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brasnu","sequence":"additional","affiliation":[{"name":"3Department of Otorhinolaryngology-Head and Neck Surgery, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Jacques","sequence":"additional","affiliation":[{"name":"8Institut National de la Sante et de la Recherche Medicale, UMR 892, Groupe de Recherche Cytokines et Re\u0301cepteurs, Institut de Biologie, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[{"name":"1EA 4054 Universite\u0301 Paris Descartes, Faculte\u0301 de Medecine; Ecole Nationale Ve\u0301te\u0301rinaire d'Alfort, Maisons-Alfort, France;"},{"name":"4Service d'Immunologie Biologique, Hopital Europe\u0301en Georges Pompidou;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,5,15]]},"reference":[{"key":"2022061623234915500_B1","doi-asserted-by":"crossref","unstructured":"McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-\u03b1 production in rheumatoid arthritis. Nat Med\u20081997; 3: 189\u201395.","DOI":"10.1038\/nm0297-189"},{"key":"2022061623234915500_B2","doi-asserted-by":"crossref","unstructured":"Ohteki T, Tada H, Ishida K, et al. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo. J Exp Med\u20082006; 203: 2329\u201338.","DOI":"10.1084\/jem.20061297"},{"key":"2022061623234915500_B3","doi-asserted-by":"crossref","unstructured":"Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol\u20082000; 164: 2832\u20138.","DOI":"10.4049\/jimmunol.164.5.2832"},{"key":"2022061623234915500_B4","doi-asserted-by":"crossref","unstructured":"Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol\u20082006; 6: 595\u2013601.","DOI":"10.1038\/nri1901"},{"key":"2022061623234915500_B5","doi-asserted-by":"crossref","unstructured":"Bulfone-Paus S, Ungureanu D, Pohl T, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med\u20081997; 3: 1124\u20138.","DOI":"10.1038\/nm1097-1124"},{"key":"2022061623234915500_B6","doi-asserted-by":"crossref","unstructured":"Yajima T, Yoshihara K, Nakazato K, et al. IL-15 regulates CD8+ T cell contraction during primary infection. J Immunol\u20082006; 176: 507\u201315.","DOI":"10.4049\/jimmunol.176.1.507"},{"key":"2022061623234915500_B7","doi-asserted-by":"crossref","unstructured":"Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R\u03b1 recycles and presents IL15 in trans to neighboring cells. Immunity\u20082002; 17: 537\u201347.","DOI":"10.1016\/S1074-7613(02)00429-6"},{"key":"2022061623234915500_B8","doi-asserted-by":"crossref","unstructured":"Yajima T, Nishimura H, Wajjwalku W, et al. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer\u20082002; 99: 573\u20138.","DOI":"10.1002\/ijc.10395"},{"key":"2022061623234915500_B9","doi-asserted-by":"crossref","unstructured":"Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood\u20082005; 105: 721\u20137.","DOI":"10.1182\/blood-2003-12-4187"},{"key":"2022061623234915500_B10","doi-asserted-by":"crossref","unstructured":"Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med\u20082006; 12: 335\u201341.","DOI":"10.1038\/nm1359"},{"key":"2022061623234915500_B11","doi-asserted-by":"crossref","unstructured":"Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A\u20082004; 101: 1969\u201374.","DOI":"10.1073\/pnas.0307298101"},{"key":"2022061623234915500_B12","doi-asserted-by":"crossref","unstructured":"Fehniger TA, Suzuki K, Ponnappan A, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med\u20082001; 193: 219\u201331.","DOI":"10.1084\/jem.193.2.219"},{"key":"2022061623234915500_B13","doi-asserted-by":"crossref","unstructured":"Baldassarre G, Fedele M, Battista S, et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci U S A\u20082001; 98: 7970\u20135.","DOI":"10.1073\/pnas.141224998"},{"key":"2022061623234915500_B14","doi-asserted-by":"crossref","unstructured":"Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst\u20082007; 99: 1257\u201369.","DOI":"10.1093\/jnci\/djm083"},{"key":"2022061623234915500_B15","doi-asserted-by":"crossref","unstructured":"Nguyen ST, Hasegawa S, Tsuda H, et al. Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma. Cancer Sci\u20082007; 98: 740\u20136.","DOI":"10.1111\/j.1349-7006.2007.00454.x"},{"key":"2022061623234915500_B16","doi-asserted-by":"crossref","unstructured":"Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res\u20082006; 12: 465\u201372.","DOI":"10.1158\/1078-0432.CCR-05-1886"},{"key":"2022061623234915500_B17","doi-asserted-by":"crossref","unstructured":"Allen C, Duffy S, Teknos T, et al. Nuclear factor-\u03baB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res\u20082007; 13: 3182\u201390.","DOI":"10.1158\/1078-0432.CCR-06-3047"},{"key":"2022061623234915500_B18","doi-asserted-by":"crossref","unstructured":"Wolf JS, Li G, Varadhachary A, et al. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res\u20082007; 13: 1601\u201310.","DOI":"10.1158\/1078-0432.CCR-06-2008"},{"key":"2022061623234915500_B19","doi-asserted-by":"crossref","unstructured":"Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor \u03b1-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol\u20082004; 173: 1681\u20138.","DOI":"10.4049\/jimmunol.173.3.1681"},{"key":"2022061623234915500_B20","doi-asserted-by":"crossref","unstructured":"Budagian V, Bulanova E, Orinska Z, et al. Natural soluble interleukin-15R\u03b1 is generated by cleavage that involves the tumor necrosis factor-\u03b1-converting enzyme (TACE\/ADAM17). J Biol Chem\u20082004; 279: 40368\u201375.","DOI":"10.1074\/jbc.M404125200"},{"key":"2022061623234915500_B21","doi-asserted-by":"crossref","unstructured":"Bulanova E, Budagian V, Duitman E, et al. Soluble interleukin IL-15R\u03b1 is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem\u20082007; 282: 13167\u201379.","DOI":"10.1074\/jbc.M610036200"},{"key":"2022061623234915500_B22","doi-asserted-by":"crossref","unstructured":"Ruckert R, Brandt K, Braun A, et al. Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo. J Immunol\u20082005; 174: 5507\u201315.","DOI":"10.4049\/jimmunol.174.9.5507"},{"key":"2022061623234915500_B23","doi-asserted-by":"crossref","unstructured":"Smith XG, Bolton EM, Ruchatz H, et al. Selective blockade of IL-15 by soluble IL-15 receptor \u03b1-chain enhances cardiac allograft survival. J Immunol\u20082000; 165: 344\u2013450.","DOI":"10.4049\/jimmunol.165.6.3444"},{"key":"2022061623234915500_B24","doi-asserted-by":"crossref","unstructured":"Mortier E, Quemener A, Vusio P, et al. Soluble interleukin-15 receptor \u03b1 (IL-15R\u03b1)-sushi as a selective and potent agonist of IL-15 action through IL-15R\u03b2\/\u03b3. Hyperagonist IL-15 \u00d7 IL-15R\u03b1 fusion proteins. J Biol Chem\u20082006; 281: 1612\u20139.","DOI":"10.1074\/jbc.M508624200"},{"key":"2022061623234915500_B25","doi-asserted-by":"crossref","unstructured":"Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood\u20082002; 99: 2114\u201321.","DOI":"10.1182\/blood.V99.6.2114"},{"key":"2022061623234915500_B26","doi-asserted-by":"crossref","unstructured":"Tartour E, Mosseri V, Jouffroy T, et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet\u20082001; 357: 1263\u20134.","DOI":"10.1016\/S0140-6736(00)04420-2"},{"key":"2022061623234915500_B27","doi-asserted-by":"crossref","unstructured":"Wittnebel S, Da Rocha S, Giron-Michel J, et al. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res\u20082007; 67: 5594\u20139.","DOI":"10.1158\/0008-5472.CAN-06-4406"},{"key":"2022061623234915500_B28","doi-asserted-by":"crossref","unstructured":"Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common \u03b3-chain cytokines. J Immunol\u20082003; 171: 2134\u201341.","DOI":"10.4049\/jimmunol.171.4.2134"},{"key":"2022061623234915500_B29","unstructured":"Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res\u20081999; 59: 3698\u2013704."},{"key":"2022061623234915500_B30","doi-asserted-by":"crossref","unstructured":"Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood\u20082003; 101: 2620\u20137.","DOI":"10.1182\/blood-2002-05-1461"},{"key":"2022061623234915500_B31","doi-asserted-by":"crossref","unstructured":"Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15\/IL-15R\u03b1 immunotherapy maximizes IL-15 activity in vivo. J Immunol\u20082006; 177: 6072\u201380.","DOI":"10.4049\/jimmunol.177.9.6072"},{"key":"2022061623234915500_B32","doi-asserted-by":"crossref","unstructured":"Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R\u03b1. Proc Natl Acad Sci U S A\u20082006; 103: 9166\u201371.","DOI":"10.1073\/pnas.0600240103"},{"key":"2022061623234915500_B33","doi-asserted-by":"crossref","unstructured":"Bernard J, Harb C, Mortier E, et al. Identification of an interleukin-15\u03b1 receptor-binding site on human interleukin-15. J Biol Chem\u20082004; 279: 24313\u201322.","DOI":"10.1074\/jbc.M312458200"},{"key":"2022061623234915500_B34","doi-asserted-by":"crossref","unstructured":"Giron-Michel J, Giuliani M, Fogli M, et al. Membrane-bound and soluble IL-15\/IL-15R\u03b1 complexes display differential signaling and functions on human hematopoietic progenitors. Blood\u20082005; 106: 2302\u201310.","DOI":"10.1182\/blood-2005-01-0064"},{"key":"2022061623234915500_B35","doi-asserted-by":"crossref","unstructured":"Becker C, Fantini MC, Schramm C, et al. TGF-\u03b2 suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity\u20082004; 21: 491\u2013501.","DOI":"10.1016\/j.immuni.2004.07.020"},{"key":"2022061623234915500_B36","doi-asserted-by":"crossref","unstructured":"Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA. IL-15\/IL-15R\u03b1-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A\u20082004; 101: 15154\u20139.","DOI":"10.1073\/pnas.0406649101"},{"key":"2022061623234915500_B37","doi-asserted-by":"crossref","unstructured":"Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck\u20082006; 28: 462\u201370.","DOI":"10.1002\/hed.20331"},{"key":"2022061623234915500_B38","unstructured":"Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res\u20082002; 8: 3137\u201345."},{"key":"2022061623234915500_B39","unstructured":"Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res\u20082002; 8: 2553\u201362."},{"key":"2022061623234915500_B40","doi-asserted-by":"crossref","unstructured":"Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol\u20082007; 7: 41\u201351.","DOI":"10.1038\/nri1995"},{"key":"2022061623234915500_B41","doi-asserted-by":"crossref","unstructured":"Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck\u20082005; 27: 771\u201384.","DOI":"10.1002\/hed.20246"},{"key":"2022061623234915500_B42","unstructured":"Kuniyasu H, Ohmori H, Sasaki T, et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res\u20082003; 9: 4802\u201310."},{"key":"2022061623234915500_B43","doi-asserted-by":"crossref","unstructured":"Colombo MP, Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res\u20082005; 65: 9113\u20136.","DOI":"10.1158\/0008-5472.CAN-05-2714"},{"key":"2022061623234915500_B44","doi-asserted-by":"crossref","unstructured":"de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer\u20082006; 6: 24\u201337.","DOI":"10.1038\/nrc1782"},{"key":"2022061623234915500_B45","doi-asserted-by":"crossref","unstructured":"Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-\u03baB is the lynchpin. Trends Immunol\u20082005; 26: 318\u201325.","DOI":"10.1016\/j.it.2005.04.003"},{"key":"2022061623234915500_B46","doi-asserted-by":"crossref","unstructured":"Lawrence T, Hageman T, Balkwill F. Cancer. Sex, cytokines, and cancer. Science\u20082007; 317: 51\u20132.","DOI":"10.1126\/science.1146052"},{"key":"2022061623234915500_B47","doi-asserted-by":"crossref","unstructured":"Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest\u20082007; 117: 1175\u201383.","DOI":"10.1172\/JCI31537"},{"key":"2022061623234915500_B48","doi-asserted-by":"crossref","unstructured":"Handisurya A, Steiner GE, Stix U, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate\u20082001; 49: 251\u201362.","DOI":"10.1002\/pros.10020"},{"key":"2022061623234915500_B49","doi-asserted-by":"crossref","unstructured":"Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest\u20082007; 117: 337\u201345.","DOI":"10.1172\/JCI29518"},{"key":"2022061623234915500_B50","doi-asserted-by":"crossref","unstructured":"Fridman JS, Caulder E, Hansbury M, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res\u20082007; 13: 1892\u2013902.","DOI":"10.1158\/1078-0432.CCR-06-2116"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/10\/3907\/2592148\/3907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/10\/3907\/2592148\/3907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:26:31Z","timestamp":1655421991000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/10\/3907\/540670\/The-Soluble-Chain-of-Interleukin-15-Receptor-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,15]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2008,5,15]]},"published-print":{"date-parts":[[2008,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-6842","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22370049","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370049.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370055","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370052.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370058","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370055.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370064.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370058.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370043.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370040.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370052","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370064","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370061.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370043","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370040","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370061","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496242.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,15]]}}}